Pulmonem Inc. was founded to demonstrate the effectiveness and safety of a reformulated and patented version of Dapsone, a generic drug, to arrest the development of inflammation caused by COVID-19 and help prevent hospitalization of those who become infected. Pulmonem has established manufacturing partnerships that will allow the Company to quickly bring this treatment to market soon after successful completion of clinical trials.
Pulmonem is also pursuing solutions for the pediatric market, as well as alternative delivery systems, such as nasal sprays and liquids.
Company Details
- Employees
- 3
- Address
- 855 Dieppe Blvd, Dieppe,new Brunswick E1a 7r8,canada
- Industry
- Biotechnology
- Website
- pulmonem.ca
- Keywords
- Show more similar pages.
- HQ
- Dieppe, New Brunswick
Pulmonem Inc. Questions
Pulmonem Inc.'s website is pulmonem.ca
Pulmonem Inc.'s LinkedIn profile is https://ca.linkedin.com/company/pulmonem-inc
Pulmonem Inc. has
3 employees.
View email and phone details for 3
employees at Pulmonem Inc..
Pulmonem Inc.'s industry is
Biotechnology
Pulmonem Inc.'s top competitors are
Mission Viejo Glass,
Pulmone Advanced Medical Devices Ltd,
Soricimed Biopharma Inc.,
Probius,
Kohana Coffee,
Triple Hair Inc.,
Hexiris,
Notogen Inc.,
Breathe Biomedical Inc.,
Avivo Biomedical Inc..
Pulmonem Inc.'s categories are Biotechnology
